Roche will use its diagnostic test for Perjeta and Kadcyla to identify patients best suited for the treatments

Roche ($RHHBY) says it will be pairing a companion diagnostic test that it uses with its breast cancer drug Herceptin to its cancer treatments Perjeta and Kadcyla. It will allow doctors to spot patients who will benefit from those treatments. Kadcyla recently won approval in the EU as a targeted cancer drug for patients with previously treated HER2-positive advanced breast cancer. The FDA signed off on it in February. The FDA last year gave approval to Perjeta for the same condition, but in September it granted it an historic approval to be used ahead of surgery as a breast cancer treatment. Some analysts are predicting mega-status for Perjeta at $8.5 billion in peak sales. Story | More


Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.